A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers一种泛KRAS抑制剂及其衍生的降解剂在KRAS驱动的癌症中表现出多方面的抗肿瘤效果Cancer CellIF44.52025-08-070OAAI
Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-d]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRASG12D InhibitorsJOURNAL OF MEDICINAL CHEMISTRYIF6.82023-11-036PRE
Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi ResistanceJOURNAL OF MEDICINAL CHEMISTRYIF6.82023-05-027PRE
Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancerONCOGENEIF7.32023-04-0526OAAI
Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancerACTA PHARMACEUTICA SINICA BIF14.62023-03-0114OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项